Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercialization Plan Should Precede Device Development – Big-Cap Firms

This article was originally published in The Gray Sheet

Executive Summary

A well-timed product iteration strategy is central to avoiding price wars with second-comers in various global markets, BD Worldwide Sales & Marketing Director Paul Falkenstein, PhD, suggested Nov. 4

You may also be interested in...



Calif. GPO Bill Gives Small Firms An Alternative To Industry Self-Patrolling

Group purchasing organization administrative fees would be capped at 3% and sole-source contracting for clinical preference items prohibited under legislation circulating in the California Senate

California Safe Needle Law Could Presage Efforts By More States, OSHA

The implementation of legislation in California designed to reduce the incidence of accidental needlesticks among health care workers may prompt additional states to enact laws mandating the use of needles and other sharps designed with protective safety features.

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel